Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
Bengt I
BI
Eriksson
Richard J
RJ
Friedman
Fred D
FD
Cushner
Michael R
MR
Lassen
D000925:Anticoagulants / Q000009:adverse effects*; D019644:Arthroplasty, Replacement, Hip / Q000401:mortality*; D019645:Arthroplasty, Replacement, Knee / Q000401:mortality*; D001384:Azetidines / Q000009:adverse effects; D001596:Benzylamines / Q000009:adverse effects; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects; D006801:Humans; D009025:Morpholines / Q000009:adverse effects; D011134:Polysaccharides / Q000009:adverse effects; D011655:Pulmonary Embolism / Q000517:prevention & control; D012107:Research Design; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects; D020246:Venous Thrombosis / Q000517:prevention & control
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D006495:Heparin, Low-Molecular-Weight; D009025:Morpholines; D011134:Polysaccharides; D013876:Thiophenes; C426686:ximelagatran; D000069552:Rivaroxaban; D000077425:Fondaparinux